Bacterial Enzymes as Targets for Drug Discovery

Dr. Kaur’s specialties include Bioinformatics, Structural Biology, X-ray Crystallography, and Rational Structure-Based Drug Design. Her research focuses on clinically relevant bacterial pathogens where a multidisciplinary approach is adopted to understand the antibacterial resistance mechanisms and design of novel inhibitory molecules. She has published more than 240 original publications, reviews and chapters in the field of bioinformatics, biophysical enzymatic activity and structural biology. Dr. Priyanka Sharma is a postdoctoral student with the biomedical Informatics department at the ICMR. Her work focuses on the field of computational biology involving structural bioinformatics and genomics of bacterial pathogens. She has published widely in the field of clinical bacteriology and is the author of over 30 research papers, reviews and chapters. She has work experience in field of antimicrobial resistance due to enzymatic mutations.

• Part I Primer of antibiotic discovery process1. Antibacterial drug discovery: A Silent Pandemic2. Current scenario and future prospective of drug discovery and development against bacterial enzymes3. Clinical diagnostics of bacterial infections and their resistance to Antibiotics — Current State and Novel Enabling Technologies Implementation Perspectives4. An Odyssey into Phylogenetic Functional Conservation of Novel Antibacterial Targets in Human Pathogens5. Validation of drug targets using molecular methodologies and enzymatic activity assays for validation of inhibitory potential6. Computational tools to identify potential drug targets in bacteria7. Antimicrobial drug resistance and bypassing strategiesPart II Bacterial enzyme as drug targets8. Designing Tomorrow's Antibiotics: Cutting-Edge Strategies and Technologies9. Inhibiting the replication by targeting topoisomerases10. Role of beta lactamases in antibiotic drug discovery11. Selective vs broad spectrum inhibition of novel outer membrane targets in Gram negatives12. Ribosomal binding antibacterial agents13. RNA polymerase: A key target for Novel Antimicrobial Therapeutic Strategies14. Colistin resistance and strategies against superbug, where we are?15. Deoxythymidine pathway enzymes as an antibacterial target16. Arresting the peptidoglycan synthesis to kill the bacteria17. Clp protease complex as a therapeutic target for tuberculosis18. PlaF: a bacterial Lands cycle phospholipase A mediating membrane phospholipid degradation and virulence adaptation19. Bacterial TIR domain-containing proteins as drug targets20. Drug Repurposing: Tackling the antibiotic resistance with existing therapeutics